The Genome Institute of Singapore, in Partnership with a Top-Ten Pharmaceutical Company, Selects Illumina's HumanRef-8 BeadChip for Gene Expression Profiling.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Illumina, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ILMN) announced today that in collaboration with a prominent pharmaceutical company, the Genome Institute of Singapore (GIS) will utilize the HumanRef-8 Expression BeadChip to analyze up to 3,000 samples. The GIS is a flagship facility in Singapore that pursues the integration of technology, genetics and biology towards the goal of individualized in·di·vid·u·al·ize tr.v. in·di·vid·u·al·ized, in·di·vid·u·al·iz·ing, in·di·vid·u·al·iz·es 1. To give individuality to. 2. To consider or treat individually; particularize. 3. medicine. "We are excited to see distinguished institutions adopt the value proposition of gene expression platforms such as the Genome Institute of Singapore," said Jay Flatley, Illumina President and Chief Executive Officer. "This collaboration, combined with agreements earlier in the year with other top pharmaceutical companies demonstrates our success and progress in this important market segment." "Illumina has become a choice microarray platform at our institute. The HumanRef-8 is to date unparalleled based on technical performance, quality of content, and value," said Lance D. Miller, PhD, Senior Group Leader of Microarray and Expression Genomics at the Genome Institute of Singapore. "I particularly like that the BeadChips are all from the same beadpool. With a sample size of nearly 3,000 this is important for generating uniform data - free of the technical noise associated with batch-to-batch variation that plagues other platforms." About HumanRef-8 Expression BeadChip The HumanRef-8 BeadChip allows researchers to generate genome-wide expression profiles for eight samples in parallel on a single microarray, with industry-leading performance. The new BeadChip is part of a complete gene expression solution that includes instrumentation, software and reagent reagent /re·a·gent/ (re-a´jent) a substance used to produce a chemical reaction so as to detect, measure, produce, etc., other substances. re·a·gent n. kits. About Illumina Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology - now used in leading genomics centers around the world - provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine  The external links in this article or section may require cleanup to comply with Wikipedia's content policies. by correlating genetic variation and gene
function with particular disease states, enhancing drug discovery,
allowing diseases to be detected earlier and more specifically, and
permitting better choices of drugs for individual patients.
"Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: this release may contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. with Affymetrix, the Company's ability to scale and integrate technology acquired from CyVera, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company's collaboration with Invitrogen, Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping Genotyping refers to the process of determining the genotype of an individual with a biological assay. Current methods of doing this include PCR, DNA sequencing, and hybridization to DNA microarrays or beads. products and applications for its platform technology, to manufacture robust Sentrix([R]) arrays - including HumanHap BeadChips - and Oligator([R]) oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion